Acceptance of physical activity monitoring in cancer patients during radiotherapy, the GIROfit phase 2 pilot trial.
Activity trackers
ECOG, Eastern cooperative group performance status
FACIT, Functional Assessment of Chronic Illness Therapy
FACT-G, Functional Assessment of Cancer Therapy General
PA, physical activity
PEG, percutaneous endoscopic gastrostomy
PWB, physical well being
Physical activity
QoL, quality of life
Radiotherapy
eHealth
ePROM, electronic patient reported outcome measures
Journal
Technical innovations & patient support in radiation oncology
ISSN: 2405-6324
Titre abrégé: Tech Innov Patient Support Radiat Oncol
Pays: England
ID NLM: 101762366
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
28
10
2021
revised:
21
02
2022
accepted:
29
03
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
In radiotherapy the timely identification of patients needing intervention and supportive care due to side effects is an important task especially in the outpatient setting. Activity trackers as an increasingly used lifestyle device may enable physicians to monitor patient's physical activity (PA) and to intervene early during the course of radiotherapy. The primary aim of this trial was to assess patient acceptance of PA monitoring in an outpatient setting and to correlate changes in PA with toxicity and changes in quality of life. Patients undergoing radio(chemo-)therapy with a curative intent were eligible to participate in this prospective pilot phase II trial. Patients were instructed to wear a commercially available activity tracker during the course of radiotherapy and four weeks afterwards. Quality of life (QoL) and fatigue was scored using the Functional assessment of Chronic Illness Therapy questionnaire. A linear regression was performed to determine baseline activity and changes in step counts during radiotherapy. We included 23 patients in this trial. Two withdrew consent before the start of treatment, two patients were excluded after prophylactic feeding tube placement and prolonged recovery. Compliance in the remaining 19 patients was high, with availability of step-counts on 92% of the days. Baseline step counts were 6274 for breast cancer patients and 3621 for patients with other entities. Decreasing activity during radiotherapy coincided with the development of side effects and declines in quality of life. Activity trackers as tool to monitor PA during and after radiotherapy were accepted by a majority of the patients included in the current trial. Observed changes in PA correlated with patient reported side effects and QoL in some of the patients.
Sections du résumé
Background
UNASSIGNED
In radiotherapy the timely identification of patients needing intervention and supportive care due to side effects is an important task especially in the outpatient setting. Activity trackers as an increasingly used lifestyle device may enable physicians to monitor patient's physical activity (PA) and to intervene early during the course of radiotherapy.
Objective
UNASSIGNED
The primary aim of this trial was to assess patient acceptance of PA monitoring in an outpatient setting and to correlate changes in PA with toxicity and changes in quality of life.
Methods
UNASSIGNED
Patients undergoing radio(chemo-)therapy with a curative intent were eligible to participate in this prospective pilot phase II trial. Patients were instructed to wear a commercially available activity tracker during the course of radiotherapy and four weeks afterwards. Quality of life (QoL) and fatigue was scored using the Functional assessment of Chronic Illness Therapy questionnaire. A linear regression was performed to determine baseline activity and changes in step counts during radiotherapy.
Results
UNASSIGNED
We included 23 patients in this trial. Two withdrew consent before the start of treatment, two patients were excluded after prophylactic feeding tube placement and prolonged recovery. Compliance in the remaining 19 patients was high, with availability of step-counts on 92% of the days. Baseline step counts were 6274 for breast cancer patients and 3621 for patients with other entities. Decreasing activity during radiotherapy coincided with the development of side effects and declines in quality of life.
Conclusions
UNASSIGNED
Activity trackers as tool to monitor PA during and after radiotherapy were accepted by a majority of the patients included in the current trial. Observed changes in PA correlated with patient reported side effects and QoL in some of the patients.
Identifiants
pubmed: 35402741
doi: 10.1016/j.tipsro.2022.03.004
pii: S2405-6324(22)00013-0
pmc: PMC8991372
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16-21Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The Department of Radiation Oncology Tübingen receives within the frame of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from Elekta AB (Stockholm, Sweden), Kaiku Health (Helsinki, Finland) TheraPanacea (Paris, France), Philips GmbH (Best, The Netherlands); Dr. Sennewald Medizintechnik GmbH (München, Germany), PTW Freiburg (Germany).
Références
Clin Breast Cancer. 2018 Feb;18(1):e1-e6
pubmed: 28916400
JMIR Res Protoc. 2021 Sep 22;10(9):e28524
pubmed: 34550079
Physiother Can. 2015 Spring;67(2):205-13
pubmed: 25931674
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):675-81
pubmed: 20133084
JAMA Oncol. 2020 Sep 1;6(9):1416-1421
pubmed: 32644104
JMIR Mhealth Uhealth. 2019 Jul 24;7(7):e12345
pubmed: 31342906
Lancet Oncol. 2006 Nov;7(11):903-9
pubmed: 17081915
Breast. 2017 Apr;32:144-155
pubmed: 28189100
Eur J Cancer. 2019 Nov;121:130-143
pubmed: 31574418
Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):716-731
pubmed: 34246737
Strahlenther Onkol. 2021 Apr;197(4):281-287
pubmed: 33211138
Evid Based Ment Health. 2017 Nov;20(4):128-133
pubmed: 29056608
NPJ Digit Med. 2018 Jul 5;1:27
pubmed: 31304309
Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1061-1065
pubmed: 28332990
Cancer Manag Res. 2018 Aug 03;10:2439-2447
pubmed: 30122993
Clin Transl Radiat Oncol. 2019 Apr 08;18:66-67
pubmed: 31341978
J Sports Med Phys Fitness. 2018 Apr;58(4):534-548
pubmed: 28488834
Cancer. 2008 Oct 15;113(8):2205-14
pubmed: 18780322
Strahlenther Onkol. 2019 May;195(5):393-401
pubmed: 30406289
JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):331-7
pubmed: 24557509